NL301203I2 - efgartigimod alfa - Google Patents

efgartigimod alfa

Info

Publication number
NL301203I2
NL301203I2 NL301203C NL301203C NL301203I2 NL 301203 I2 NL301203 I2 NL 301203I2 NL 301203 C NL301203 C NL 301203C NL 301203 C NL301203 C NL 301203C NL 301203 I2 NL301203 I2 NL 301203I2
Authority
NL
Netherlands
Prior art keywords
efgartigimod
alfa
efgartigimod alfa
Prior art date
Application number
NL301203C
Other languages
English (en)
Dutch (nl)
Other versions
NL301203I1 (en17
Original Assignee
argenx BV
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52347464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301203(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by argenx BV, Univ Texas filed Critical argenx BV
Publication of NL301203I1 publication Critical patent/NL301203I1/nl
Publication of NL301203I2 publication Critical patent/NL301203I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
NL301203C 2013-12-24 2022-11-03 efgartigimod alfa NL301203I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920547P 2013-12-24 2013-12-24
PCT/US2014/072087 WO2015100299A1 (en) 2013-12-24 2014-12-23 Fcrn antagonists and methods of use

Publications (2)

Publication Number Publication Date
NL301203I1 NL301203I1 (en17) 2022-11-09
NL301203I2 true NL301203I2 (nl) 2023-05-24

Family

ID=52347464

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301203C NL301203I2 (nl) 2013-12-24 2022-11-03 efgartigimod alfa

Country Status (26)

Country Link
US (3) US10316073B2 (en17)
EP (2) EP3087095B1 (en17)
JP (2) JP6554473B2 (en17)
KR (3) KR102452173B1 (en17)
CN (2) CN112142843B (en17)
AU (1) AU2014369999B2 (en17)
BR (1) BR112016014810B1 (en17)
CA (1) CA2934644C (en17)
DK (1) DK3087095T3 (en17)
EA (1) EA035324B1 (en17)
ES (1) ES2742682T3 (en17)
FI (1) FIC20230003I1 (en17)
FR (1) FR23C1004I2 (en17)
HU (2) HUE046822T2 (en17)
IL (1) IL246223B (en17)
LT (2) LT3087095T (en17)
LU (1) LUC00284I2 (en17)
MX (1) MX368804B (en17)
NL (1) NL301203I2 (en17)
NO (1) NO2022049I1 (en17)
NZ (1) NZ722055A (en17)
PL (1) PL3087095T3 (en17)
PT (1) PT3087095T (en17)
SG (2) SG10202009832XA (en17)
WO (1) WO2015100299A1 (en17)
ZA (1) ZA201604464B (en17)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014369999B2 (en) 2013-12-24 2019-12-12 The Board Of Regents Of The University Of Texas System FcRn antagonists and methods of use
KR102720769B1 (ko) * 2015-03-09 2024-10-22 아르제넥스 비브이 FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
CN106957364B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb12及其应用
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
JP7295799B2 (ja) * 2016-12-02 2023-06-21 ザ テキサス エー アンド エム ユニバーシティー システム 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
MX2020005981A (es) * 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
AU2019283673B2 (en) 2018-06-08 2023-12-07 argenx BV Compositions and methods for treating immune thrombocytopenia
AU2019307959A1 (en) * 2018-07-20 2021-02-04 Momenta Pharmaceuticals, Inc. FcRn antibody compositions
WO2020054979A1 (ko) * 2018-09-12 2020-03-19 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
AU2020286968A1 (en) * 2019-06-07 2021-11-25 argenx BV Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
MD4087875T2 (ro) 2020-01-08 2025-02-28 argenx BV Antagoniști ai receptorului FC neonatal uman (FCRN) pentru tratarea afecțiunilor pemfigusului
TWI869542B (zh) * 2020-02-10 2025-01-11 大陸商北京拓界生物醫藥科技有限公司 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途
CN113769058B (zh) * 2020-06-10 2024-09-06 上海宝济药业股份有限公司 一种药物组合及其应用
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN117580857A (zh) 2021-06-23 2024-02-20 美国政府(由卫生和人类服务部的部长所代表) Apoc-ii短模拟肽及使用方法
WO2023139107A1 (en) 2022-01-18 2023-07-27 argenx BV Galectin-10 antibodies
IL315112A (en) 2022-02-21 2024-10-01 argenx BV Methods of treating myositis with FCRN antagonists
JP2025512483A (ja) 2022-04-13 2025-04-17 オーエスイー・イミュノセラピューティクス 抗体を選択的に排除するための分子の新規のクラス
EP4519300A1 (en) 2022-05-05 2025-03-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Short apolipoprotein e mimetic peptides and methods of use
AU2023291783A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn binding molecules and methods of use
CN115645537A (zh) * 2022-10-25 2023-01-31 成都臻拓医药科技有限公司 FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途
WO2024105445A2 (en) * 2022-11-14 2024-05-23 argenx BV Fcrn antagonist molecules and methods of use thereof
WO2024163894A1 (en) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024206214A1 (en) * 2023-03-24 2024-10-03 Paragon Therapeutics, Inc. Fc fragments that bind fcrn and methods of use
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
WO2025017368A1 (en) 2023-07-16 2025-01-23 argenx BV Methods of treating chronic inflammatory demyelinating polyneuropathy
WO2025057086A2 (en) 2023-09-11 2025-03-20 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions of fcrn antibodies
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
CA2210656C (en) 1995-01-17 2011-07-05 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
US20040047862A1 (en) 2000-11-20 2004-03-11 Lazarus Alan H. Method for treating thrombocytopenia with monoclonal ivig
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP3945281B2 (ja) 2002-03-19 2007-07-18 富士ゼロックス株式会社 画像形成装置
US7351803B2 (en) 2002-05-30 2008-04-01 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
EP2345671B8 (en) 2002-09-27 2023-01-11 Xencor, Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
BRPI0406662A (pt) 2003-01-09 2005-12-20 Macrogenics Inc Vetor, célula, método de identificar um mab, e, composição
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1798864A4 (en) 2004-09-30 2013-07-31 Brother Ind Ltd WIRELESS LABEL COMMUNICATION DEVICE, WIRELESS LABEL, WIRELESS COMMUNICATION SYSTEM AND METHOD OF WIRELESS COMMUNICATION
EP1879920A2 (en) * 2005-04-29 2008-01-23 The Jackson Laboratory Fcrn antibodies and uses thereof
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
AU2008254951A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
WO2008151088A2 (en) * 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
US8195661B2 (en) 2007-11-27 2012-06-05 Umber Systems Method and apparatus for storing data on application-level activity and other user information to enable real-time multi-dimensional reporting about user of a mobile data network
US9260525B2 (en) * 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
NO2486141T3 (en17) 2009-10-07 2018-06-09
TWI542597B (zh) * 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
GB201111291D0 (en) 2011-06-30 2011-08-17 Agco Int Gmbh Engine control system
EP3378489A1 (en) 2011-10-26 2018-09-26 Elanco Tiergesundheit AG Monoclonal antibodies and methods of use
US20140302028A1 (en) 2011-11-18 2014-10-09 Merck Sharp & Dohme Corp. Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
PL2870247T3 (pl) 2012-07-05 2019-10-31 Hoffmann La Roche Układ ekspresji i wydzielania
GB201302878D0 (en) 2013-02-19 2013-04-03 Argen X Bv Modified igG molecules
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
EP3663763B1 (en) 2013-11-26 2022-02-16 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
AU2014369999B2 (en) 2013-12-24 2019-12-12 The Board Of Regents Of The University Of Texas System FcRn antagonists and methods of use
DK3193930T3 (da) 2014-09-17 2019-08-26 Affibody Ab Nye polypeptider
DK3250610T3 (da) 2015-01-30 2023-10-30 Momenta Pharmaceuticals Inc Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
KR102720769B1 (ko) 2015-03-09 2024-10-22 아르제넥스 비브이 FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법
CA3022547A1 (en) 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
US10507234B2 (en) 2015-07-17 2019-12-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with Fc-coupled antigens
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
GB201618424D0 (en) 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
AU2019283673B2 (en) 2018-06-08 2023-12-07 argenx BV Compositions and methods for treating immune thrombocytopenia
JP2022532229A (ja) 2019-05-17 2022-07-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド 天疱瘡及び類天疱瘡疾患の治療における抗ＦｃＲｎ抗体の使用
AU2020286968A1 (en) * 2019-06-07 2021-11-25 argenx BV Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration

Also Published As

Publication number Publication date
CA2934644A1 (en) 2015-07-02
LUC00284I2 (en17) 2025-05-12
EP3626738A1 (en) 2020-03-25
EA201691304A1 (ru) 2016-10-31
NO2022049I1 (no) 2022-11-23
BR112016014810A2 (pt) 2017-09-19
ES2742682T3 (es) 2020-02-17
ZA201604464B (en) 2025-05-28
LT3087095T (lt) 2019-09-10
HUS2200048I1 (hu) 2022-12-28
HUE046822T2 (hu) 2020-03-30
PT3087095T (pt) 2019-10-09
WO2015100299A1 (en) 2015-07-02
EP3087095B1 (en) 2019-08-07
DK3087095T3 (da) 2019-10-28
KR20160111937A (ko) 2016-09-27
KR102452173B1 (ko) 2022-10-17
CA2934644C (en) 2023-11-21
PL3087095T3 (pl) 2020-03-31
AU2014369999A1 (en) 2016-07-07
NL301203I1 (en17) 2022-11-09
JP2017501725A (ja) 2017-01-19
JP2019076103A (ja) 2019-05-23
CN112142843B (zh) 2024-10-18
CN106103476B (zh) 2020-11-27
NZ722055A (en) 2020-02-28
BR112016014810B1 (pt) 2023-12-26
US11505585B2 (en) 2022-11-22
SG11201605203UA (en) 2016-07-28
EP3087095A1 (en) 2016-11-02
LTPA2022014I1 (en17) 2022-12-12
US20180179258A1 (en) 2018-06-28
JP6554473B2 (ja) 2019-07-31
EA035324B1 (ru) 2020-05-28
SG10202009832XA (en) 2020-11-27
FIC20230003I1 (fi) 2023-01-19
CN106103476A (zh) 2016-11-09
IL246223B (en) 2021-06-30
FR23C1004I1 (fr) 2023-03-10
MX2016008399A (es) 2016-12-15
KR20240033084A (ko) 2024-03-12
IL246223A0 (en) 2016-07-31
FR23C1004I2 (fr) 2024-01-05
US20220275035A1 (en) 2022-09-01
US20150218239A1 (en) 2015-08-06
US10316073B2 (en) 2019-06-11
CN112142843A (zh) 2020-12-29
MX368804B (es) 2019-10-17
AU2014369999B2 (en) 2019-12-12
KR20220152546A (ko) 2022-11-16

Similar Documents

Publication Publication Date Title
FIC20230003I1 (fi) Efgartigimodi alfa
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
UY4298S (es) Carcasa
DK3077047T3 (da) Aramcholsalte
DK2956698T3 (da) Bindestrimler
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK3052081T3 (da) Pastil
EP2952513A4 (en) AZOLE AND BENZENE DERIVATIVE
DK2946640T3 (da) Langmuir-probe
EP2969096A4 (en) Bottle pressurization delivery system
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2943489A4 (en) DEUTERATED MOMELOTINIB
EP2970310A4 (en) 5-BROMO-indirubins
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
FI10138U1 (fi) Kelkkateltta
ES1078715Y (es) Mosquitera
DE112014005422A5 (de) Friktionsfalschdrallaggregat
BR112016000501A2 (pt) Nalador
UY4342S (es) Carcasa